Successful Desensitization to Alemtuzumab, With Flow Cytometry Analysis of Peripheral Blood Cells

J Investig Allergol Clin Immunol. 2022 Dec 15;32(6):501-503. doi: 10.18176/jiaci.0795. Epub 2022 Feb 28.

J Costa Carvalho¹, M C Macário², S Batista², I Alen Coutinho¹, P Laranjeira^{3

4

5

6}, C Loureiro¹, A Paiva^{3

4

5

7}, A Todo Bom^{1

8}

¹ Allergy and Clinical Immunology Department, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal.
² Neurology Department, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal.
³ Flow Cytometry Unit, Clinical Pathology Department, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal.
⁴ Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
⁵ Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal.
⁶ Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal.
⁷ Instituto Politécnico de Coimbra, ESTESC-Coimbra Health School, Ciências Biomédicas Laboratoriais, Coimbra, Portugal.
⁸ Institute of Pathophysiology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

No abstract available

Keywords: Alemtuzumab; Desensitization; Flow cytometry; Hypersensitivity; Multiple sclerosis.

MeSH terms